Antiviral activity
DRUG WITHDRAWAL
The level of HBV DNA decreased profoundly from baseline in the patients receiving three doses of Canocapavir but not in those receiving placebo. The HBV DNA level decreased greatly starting from day 8, with the average maximum decrease on day 22 or day 29. The HBV DNA level gradually returned to the baseline after drug withdrawal and recovered to the baseline at follow-up on day 57. Moreover, the HBV DNA level decreased overwhelmingly in patients who received 100 mg or 200 mg of Canocapavir compared to those who received 50 mg. The mean maximum HBV DNA decreases were -1.54, -2.50, -2.75, and -0.47 logChanges of HBV virologic markers from baseline during treatment with Canocapavir or placebo. This study also showed that the HBV pgRNA level decreased profoundly from baseline in the patients who received different doses of Canocapavir but not in those who received the placebo. As mentioned above, the declining trend was similar to that of HBV DNA. The degree of HBV pgRNA decrease in the patients who received 100 mg or 200 mg of Canocapavir was similar, but it was deeper than that in the patients who received 50 mg. The mean maximum HBV pgRNA decreases were -1.53, -2.35, -2.34, and -0.17 logIn addition, within the duration of treatment, the HBcrAg level in each dosage cohort decreased to a certain extent from baseline. The HBcrAg level decreased more in the patients who received 100 mg or 200 mg of Canocapavir than in those who received 50 mg of Canocapavir or the placebo. The maximum mean HBcrAg decreases were -0.30, -0.61, -0.51, and -0.38 log